Exagen Inc. Appoints Michael Mahler as Chief Scientific Officer

Published: 2025-06-23 13:20:23 ET XGN

Published on 06/23/2025 at 13:20

Exagen Inc. announced the appointment of Dr. Michael Mahler as Chief Scientific Officer. With an extensive background in immunology and autoimmune research, Dr. Mahler brings a wealth of expertise to Exagen's mission of improving the diagnosis and treatment of autoimmune diseases. Dr. Mahler received his Ph.D. from the Institute of Molecular Genetics at the University of Heidelberg, Germany.

During his doctoral research, he worked at the Scripps Research Institute, more specifically in the lab of Prof. Eng Tan and Michael Pollard, pioneers in autoimmune research. At the same time, Dr. Mahler initiated a productive and lasting collaboration with one of his mentors, Dr. Marvin J. Fritzler, a thought leader in the field whose research spans a wide range of topics, including autoimmune disease, the biology of autoantigens, and novel diagnostic technologies. Over the course of his distinguished career, Dr. Mahler has held key positions at various diagnostic companies, most recently serving as Senior Vice President of Research Development and Business Development at Werfen.

His transformative work has led to the discovery of several novel autoantigens and the development of innovative diagnostic solutions. His scientific contributions have resulted in over 300 peer-reviewed publications and numerous patents, advancing the accurate diagnosis of autoimmune diseases. In his new role at Exagen, Dr. Mahler will spearhead strategic initiatives aimed at enhancing precision diagnostics for autoimmune diseases.

His expertise will support Exagen's development of cutting-edge tools to improve patient outcomes.